Sec Form 4 Filing - Versant Venture Capital VI, L.P. @ LENZ Therapeutics, Inc. - 2024-03-21

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Versant Venture Capital VI, L.P. 2. Issuer Name and Ticker or Trading Symbol LENZ Therapeutics, Inc. [ LENZ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) ONE SANSOME STREET, SUITE 1650 3. Date of Earliest Transaction (MM/DD/YY) 03/21/2024 (Street) SAN FRANCISCO, CA94104 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/21/2024 J( 1 ) 598,203 A 842,162 ( 2 ) I See footnote ( 3 ) Common Stock 2,101,199 ( 2 ) D ( 4 ) Common Stock 1,598,789 I See footnote ( 5 ) ( 6 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Versant Venture Capital VI, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO, CA94104 X Versant Ventures VI GP, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO, CA94104 X Versant Ventures VI GP-GP, LLC ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO, CA94104 X Versant Vantage II, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO, CA94104 X Versant Vantage II GP, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO, CA94104 X Versant Vantage II GP-GP, LLC ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO, CA94104 X Versant Venture Capital VII, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO, CA94104 X Versant Ventures VII GP, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO, CA94104 X Versant Ventures VII GP-GP, LLC ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO, CA94104 X Signatures Versant Vantage II, LP By: Versant Vantage II GP, L.P. Its: General Partner By: Versant Vantage II GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer 03/25/2024 Signature of Reporting Person Date Versant Vantage II GP, L.P., By: Versant Vantage II GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer 03/25/2024 Signature of Reporting Person Date Versant Vantage II GP-GP, LLC, By: /s/ Max Eisenberg Its: Chief Operating Officer 03/25/2024 Signature of Reporting Person Date Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer 03/25/2024 Signature of Reporting Person Date Versant Ventures VI GP, L.P., By: Versant Ventures VI GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer 03/25/2024 Signature of Reporting Person Date Versant Ventures VI GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer 03/25/2024 Signature of Reporting Person Date Versant Venture Capital VII, L.P. By: Versant Ventures VII GP, L.P. Its: General Partner By: Versant Ventures VII GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer 03/25/2024 Signature of Reporting Person Date Versant Ventures VII GP, L.P., By: Versant Ventures VII GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer 03/25/2024 Signature of Reporting Person Date Versant Ventures VII GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer 03/25/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These shares were acquired pursuant to that certain Agreement and Plan of Merger by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), and Lenz Therapeutics, Inc., a Delaware corporation ("LENZ"), pursuant to which the Merger Sub merged with and into LENZ (the "Merger"), with LENZ continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the Merger. ( 2 )Effective March 21, 2024, prior to the closing of the Merger, the Issuer effected a one-for-seven reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. ( 3 )These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein. ( 4 )These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. ( 5 )These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII disclaims beneficial ownership of the shares held by VVC VII, except to the extent of their respective pecuniary interests therein. ( 6 )VVC VII's acquisition of these shares pursuant to the Merger was previously reported on a Form 3 filed on March 25, 2024.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.